Prefer Newsweek on Google to see more of our trusted coverage when you search. In 2025, biotechnology stocks had their best year since the COVID-19 pandemic, with the market sector’s two major indexes ...

Biotech stocks are emerging from a four-year slump. The SPDR S&P Biotech exchange-traded fund XBI, a proxy for the sector, is up 25% so far this year through Oct. 31, beating the S&P 500 SPX by 9 ...

From AI-designed drugs to lab-grown organs, biotech in 2026 is redefining what’s possible in medicine. Emerging companies are leading FDA approvals, advancing life-saving therapies, and pioneering ...

The Fight of Our Lives highlights biotech’s impact on patient lives in both the short- and long-term, urging continued ...

Doubling survival in pancreatic cancer, a long-fought rare disease approval, a massive IPO and ambitious biotech ...

The promise of a better pan-RAS inhibitor Erasca has been described as the poor man’s Revolution Medicines. Impoverished ...

Slow rolling chaos at the FDA and its effects on drug approvals. How to think about risk when investing in biotech. A review of results from DNA researcher Twist Bioscience. Don't wait! Be sure to get ...

Legend Biotech (NASDAQ: LEGN) was one of the healthier healthcare stocks on the market as the trading week kicked off on ...